key: cord-0846235-6jjivsc2
authors: Palich, R.; Veyri, M.; Marot, S.; Vozy, A.; Gligorov, J.; Maingon, P.; Marcelin, A.-G.; Spano, J.-P.
title: Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients
date: 2021-04-29
journal: Ann Oncol
DOI: 10.1016/j.annonc.2021.04.020
sha: 101ea628560e6aad87fffb40c0750e4a1329b088
doc_id: 846235
cord_uid: 6jjivsc2

nan

Active cancer and ongoing antineoplastic treatments are major factors for severe and death, reasons why the SARS-CoV-2 vaccination remains a priority in cancer patients (CPs) [1] . However, immunocompromised patients were excluded from major studies on mRNA vaccines [2, 3] , and could have a decreased response to vaccination, as recently demonstrated in solid organ transplant recipients [4] . Herein, we aimed to assess the proportion of antibody response 4 weeks after the first injection of the BNT162b2 (Pfizer-BioNTech) vaccine in CPs and health care workers (HCWs) as the control population.

All consecutive patients with cancer on active treatment or with treatment in the two last years and HCWs who underwent SARS-CoV-2 vaccination between 17/02/2021 and 18/03/2021 at the Pitié-Salpêtrière hospital, Paris, France, were selected for analysis. The titration of SARS-CoV-2 antibodies was proposed just before the second injection of SARS-CoV-2 antibodies were measured in 110 CPs and 25 HCWs (Table) . In CPs who did not have COVID-19 before vaccination, the seroconversion rate was only 55%, while it reached J o u r n a l P r e -p r o o f 100% in HCWs. Titers of anti-S IgG were significantly higher in HCWs in comparison with seropositive CPs (680 versus 315 UA/mL, p=0.04). Gender, cancer locations and metastatic status were similar in seroconverters and non-seroconverters CPs (Supplementary Table) .

After adjustment for potential confounders, two factors were strongly associated with no seroconversion: age over 65 (odds-ratio 3.58, 95%CI 1.40-9.15, p=0.008) and treatment by chemotherapy (odds-ratio 4.34, 95%CI 1.67-11.30, p=0.003).

No symptomatic COVID-19 occurred between the two injections of vaccine in CPs and HCWs.

In summary, almost half CPs showed no anti-spike antibody response after a first injection of BNT162b2 vaccine, and this low seroconversion rate could be much worse in elderly patients and in patients under chemotherapy. In comparison, 100% of the HCWs had anti-spike seroconversion. Moreover, even in CPs with seroconversion, the level of antibody response could be lower than expected.

In conclusion, our findings argue for not extending the 21-day period between the two SARS-CoV-2 vaccine injections in CPs, and for performing serological monitoring to assess antibody response in this particular population, that could lead to adapt this vaccine strategy. We would also recommend a vaccination strategy including family and friendship circles. 

COVID-19 and Cancer: a Comprehensive Review

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

J o u r n a l P r e -p r o o f